AI Access Brief Podcast
AI Generated Daily briefings on HEOR, HTA strategy and the evidence access landscape. For pharmaceutical and biotech professionals navigating regulatory-payer alignment, HTA submissions, and evidence strategy.
AI Access Brief Podcast
HTA Framework Evolution & Digital Guidance
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
Welcome to the Access Brief, your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us today.
SPEAKER_00And I'm Sarah. Always good to be here. And I'll say I've had today's topics circled since this morning, particularly the WHO framework piece.
SPEAKER_01Same here. We're looking at the WHO's new HTA framework for low-income countries, a significant shift in global evidence standards, then TGA's updated digital therapeutics guidance, which could reshape how we validate these technologies, and CATS combination products pilot, addressing a critical evidence gap. Finally, NICE's evolving global standards influence Anshent Surwatsatz, signaling broader methodological convergence.
SPEAKER_00That second one is interesting to me. So the budget impact question for digital therapeutics remains unresolved, especially when you consider implementation costs versus therapeutic value. Payers will need more granular data.
SPEAKER_01Exactly. Let's get into it. Starting with the WHO HTA framework for low-income countries. This isn't just guidance. It's a structural attempt to standardize evidence generation where resources are constrained. What strikes me is the focus on pragmatic trial designs and simplified economic models.
SPEAKER_00Pragmatic designs make sense contextually, but I wonder if that's the full picture, though. The framework doesn't adequately address how to handle opportunity cost in systems with near zero budgets. When every dollar is contested, simplified models might overlook trade-offs.
SPEAKER_01That's fair, though I think payers would see differently here. The WHO is explicitly acknowledging that traditional cost-effectiveness thresholds don't apply when GDP per capita is below $1,000. Instead, they're emphasizing comparative effectiveness and feasibility, right? And from the payer side, this foster, that's actually a recognition that value isn't solely monetary.
SPEAKER_00The part that gives me pause is the reliance on real-world evidence from high-income settings. Transferring RWE across vastly different healthcare infrastructures carries methodological risks. We've seen this in oncology outcomes where biomarker prevalence varies dramatically.
SPEAKER_01What's striking here is the WHO's emphasis on local capacity building, training HTA officers alongside evidence generation. That's a long-term play for sustainable access.
SPEAKER_00And what's interesting is how this could influence multinational pricing strategies. If low-income countries adopt standardized evidence requirements, manufacturers might develop tiered HEOR packages from the outset. But will that undermine differential pricing models?
SPEAKER_01That connects to something I keep coming back to: the tension between global standardization and local adaptation. The WHO framework seems to be navigating that by focusing on core methodological principles rather than rigid thresholds. Worth watching how quickly African and Asian HTA bodies adopt this.
SPEAKER_00Shifting to TGA's Digital Therapeutics Guidance. This feels like a critical moment. Australia's regulator is finally formalizing how to evaluate software as medical devices. The emphasis on clinical utility validation and real world performance monitoring is particularly noteworthy.
SPEAKER_01Clinical utility is indeed the centerpiece, but I'd push back slightly on that. The guidance doesn't sufficiently address how to handle dynamic algorithms that evolve post-approval. What happens when an app's machine learning model updates after initial assessment? That's a regulatory and evidence gap.
SPEAKER_00That's one read. I'd frame it slightly differently. The TGA is actually ahead of many regulators by requiring continuous performance monitoring through registries. They're essentially building pharmacovigilance frameworks for DTX, which is necessary given the iterative nature of these technologies.
SPEAKER_01The part that gives me pause is the evidence threshold. They're demanding RCT data for initial approval, which may stifle innovation for smaller companies developing niche digital interventions. This could inadvertently favor big players with deeper pockets.
SPEAKER_00Honestly, this one caught me off guard. I expected more flexibility given DTX's lower development costs, but the TGA's concern about inconsistent performance across diverse populations is valid, especially when you consider digital literacy gaps affecting adorants. The budget impact question there is one the field hasn't fully worked out yet.
SPEAKER_01Right, and from the payer side, that's precisely why they're insisting on robust utility data. If these tools don't demonstrably improve outcomes or reduce system costs, uh the issue at Mauras, the sustainability argument, collapses. The guidance implicitly requires DTX to prove they're not just nice to have but necessary.
SPEAKER_00What's striking here is the parallel to HTA evolution for gene therapies. Both require new evidence paradigms. The TGA might be setting a precedent for how regulators handle software-based interventions globally.
SPEAKER_01Now to Kath's combination products pilot. This addresses a persistent pain point, assessing products that blend drugs, devices, and software. The pilot's focus on modular evidence packages and stakeholder collaboration seems promising.
SPEAKER_00Modular evidence packages make practical sense, but I wonder about the methodological rigor. How do you standardize evidence for components with different risk profiles? A drug's safety data doesn't automatically validate a connected device's performance.
SPEAKER_01That's fair, though I think payers would see this as a pragmatic solution. CATH is essentially creating a framework where evidence can be accumulated incrementally, right? And from the payer side, that's crucial when dealing with complex innovations where traditional trials may not capture real-world use.
SPEAKER_00The part that gives me pause is the timeline. Pilots often take years to mature, and by then these technologies may have evolved. We saw this with AI-powered diagnostics, where assessment lagged innovation cycles.
SPEAKER_01Historical precedent shows that pilot programs often accelerate when industry engagement is strong. What's interesting here is CAT's requirement for joint development of assessment tools with manufacturers. That could streamline the process but raises questions about independence.
SPEAKER_00And what's interesting is how this could influence combination product development pathways. If HTA bodies provide early clarity on evidence requirements, companies might design trials with modular endpoints from the outset. But will that compromise holistic assessment?
SPEAKER_01This connects to the broader theme of HTA adapting to innovation. The pilot isn't just about assessment, it's about creating a new evidence ecosystem. Worth watching if other HTA bodies follow Catheath's lead.
SPEAKER_00Finally, NICE's evolving global standards influence. The UK agency is increasingly shaping HTA methodologies beyond its borders, particularly in Asia Pacific and the Middle East. Their approach to value assessment frameworks seems to be gaining traction.
SPEAKER_01Their focus on multi-criteria decision analysis and incorporating social value is particularly influential, but I'd push back slightly. NICE's emphasis on equity adjustments doesn't always translate to systems with different healthcare priorities or resource constraints.
SPEAKER_00That's one read. I'd frame it slightly differently. NICE isn't exporting thresholds but methodological principles. Their value framework's adaptability is what makes it appealing to emerging HTA systems, looking for structure without rigid cost effectiveness requirements.
SPEAKER_01The part that gives me pause is the pace of adoption. While many countries reference NICE, implementation varies. We've seen jurisdictions adopt their thresholds but ignore equity adjustments, leading to inconsistent value judgments.
SPEAKER_00Honestly, this one caught me off guard. I expected more resistance given post-Brexit sovereignty concerns. But NICE's pragmatic approach, providing adaptable tools rather than prescriptive rules, seems to be resonating. The budget impact question for global standardization is complex when you consider varying healthcare system capacities.
SPEAKER_01What's striking here is how this reflects a shift toward HTA harmonization. NICE isn't just leading, it's facilitating a shared language for value assessment that could eventually streamline multinational submissions.
SPEAKER_00And what's interesting is how this interacts with the WHO framework we discussed earlier. If low-income countries adopt NICE's principles while leveraging WHU's low resource adaptations, we might see a truly global evidence ecosystem emerging. A lot to think about today. I'll be watching how the WHO framework influences real-world evidence generation in low resource settings and whether TGA's digital guidance creates a template for other regulators.
SPEAKER_01We'll be back tomorrow. Show notes and transcripts at outcomes dash analytica.no. See you then. Thanks for listening. See you tomorrow. Back tomorrow on AccessBrief. Show notes at outcomes dash analytica.no.